Global Blood Therapeutics, Inc. (NASDAQ:GBT) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday.
A number of other research firms have also recently issued reports on GBT. Oppenheimer Holdings, Inc. set a $53.00 target price on Global Blood Therapeutics and gave the company a “buy” rating in a research report on Monday. Zacks Investment Research upgraded Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a research report on Tuesday, October 10th. Needham & Company LLC set a $51.00 target price on Global Blood Therapeutics and gave the company a “buy” rating in a research report on Wednesday, October 18th. Morgan Stanley reiterated an “overweight” rating and issued a $56.00 target price (up previously from $51.00) on shares of Global Blood Therapeutics in a research report on Friday, October 6th. Finally, J P Morgan Chase & Co reiterated a “buy” rating on shares of Global Blood Therapeutics in a research report on Monday, October 23rd. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $54.08.
Global Blood Therapeutics (NASDAQ:GBT) last released its earnings results on Tuesday, November 7th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.04). During the same quarter in the previous year, the company posted ($0.58) earnings per share.
ILLEGAL ACTIVITY NOTICE: “BidaskClub Upgrades Global Blood Therapeutics, Inc. (GBT) to “Buy”” was first published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/11/03/bidaskclub-upgrades-global-blood-therapeutics-inc-gbt-to-buy.html.
In related news, VP Peter Radovich sold 12,500 shares of Global Blood Therapeutics stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $35.00, for a total value of $437,500.00. Following the transaction, the vice president now directly owns 2,684 shares of the company’s stock, valued at $93,940. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Charles J. Homcy sold 70,000 shares of Global Blood Therapeutics stock in a transaction that occurred on Friday, October 27th. The stock was sold at an average price of $33.97, for a total value of $2,377,900.00. Following the completion of the transaction, the director now directly owns 83,328 shares in the company, valued at $2,830,652.16. The disclosure for this sale can be found here. Insiders have sold 91,500 shares of company stock worth $3,093,350 over the last three months. Insiders own 5.30% of the company’s stock.
Several institutional investors have recently bought and sold shares of GBT. BlackRock Inc. lifted its stake in shares of Global Blood Therapeutics by 4,675.5% in the first quarter. BlackRock Inc. now owns 2,618,847 shares of the company’s stock worth $96,503,000 after acquiring an additional 2,564,008 shares during the period. State Street Corp lifted its stake in shares of Global Blood Therapeutics by 217.9% in the second quarter. State Street Corp now owns 2,138,323 shares of the company’s stock worth $58,479,000 after acquiring an additional 1,465,595 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Global Blood Therapeutics in the second quarter worth approximately $26,919,000. Vanguard Group Inc. lifted its stake in shares of Global Blood Therapeutics by 40.1% in the first quarter. Vanguard Group Inc. now owns 2,535,980 shares of the company’s stock worth $93,451,000 after acquiring an additional 726,366 shares during the period. Finally, PDT Partners LLC acquired a new position in shares of Global Blood Therapeutics in the second quarter worth approximately $7,702,000. 86.22% of the stock is currently owned by institutional investors.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
What are top analysts saying about Global Blood Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Global Blood Therapeutics Inc. and related companies.